Scpharmaceutical SEC Filings

scPharmaceuticals Inc. had a Schedule 13G filing showing that Luther King Capital Management Corporation and J. Luther King, Jr. each report beneficial ownership of 2,128,391 shares, representing 4.0% of the outstanding common stock. The filing reports that the reporting persons have sole voting and sole dispositive power over these shares and that the holdings were acquired and are held in the ordinary course of business, not to influence control of the issuer. The filing classifies the institutional filer as an investment adviser/controller and confirms no shared voting or dispositive power and no group or 5%+ ownership status.

scPharmaceuticals insider transactions tied to merger consideration: The reporting person, Leonard D. Schaeffer, reported that on 10/07/2025 non‑derivative holdings totaling 111,900 shares were disposed (68,796 direct; 43,104 indirect) in connection with a completed tender offer and merger. Tendering shareholders received $5.35 per share in cash plus one non‑tradable contingent value right (CVR) that may pay up to $1.00 per CVR upon achievement of specified regulatory and net‑sales milestones. Outstanding stock options with exercise prices below $5.35 were cancelled and converted into cash payments and one CVR per underlying share; the reporting person’s affected options totaling 66,050 (30,000; 19,750; 16,300) were reported as disposed.

scPharmaceuticals Inc. (SCPH) Form 4 filed for director Klaus R. Veitinger reports changes tied to a merger transaction completed on 10/07/2025. Pursuant to an Agreement and Plan of Merger with MannKind Corporation, a tender offer and related merger mechanics caused all outstanding company options with an exercise price below $5.35 to be cancelled and converted. Four option grants exercisable for a total of 72,174 underlying shares were cancelled: 30,000 @ $3.85, 19,750 @ $4.11, 16,300 @ $4.53, and 6,124 @ $3.37. Each cancelled option holder will receive cash equal to the excess of $5.35 over the option exercise price multiplied by the number of shares, plus one contingent value right (CVR) per share, subject to withholding.

Insider report summary: A Form 4 filed for Abraham William Tober, a director of scPharmaceuticals Inc. (SCPH), discloses cancellation of multiple outstanding stock options and conversion mechanics tied to a merger with MannKind Corporation. On 10/07/2025 the reporting person had three option grants cancelled and treated as dispositions: 30,000, 19,750, and 16,300 option shares. Under the Merger Agreement, Company Options with exercise prices below $5.35 were cancelled and converted into (i) a cash payment equal to the excess of $5.35 over the option exercise price times the number of shares and (ii) one contingent value right per share.

The Form 4 lists the options as disposed (Transaction Code D) on 10/07/2025 and shows 0 shares of common stock resulting from these specific derivative holdings after the transactions.

scPharmaceuticals Inc. (SCPH) reported that on 10/07/2025 a reporting person canceled a set of stock options in connection with a completed tender offer under an Agreement and Plan of Merger with MannKind Corporation. A series of Company Options with exercise prices below $5.35 were cancelled and converted into a cash payment equal to the per‑share spread between $5.35 and each option's exercise price, and into one contingent value right (CVR) per underlying share.

The Form 4 lists five option grants totaling 84,422 underlying shares canceled: strikes of $3.85, $4.11, $4.53, $3.37, and $4.80, with varying expiration dates between 06/18/2029 and 06/03/2035. The filing is administrative evidence of the merger consideration mechanics for option holders: immediate cash for intrinsic value and CVRs for additional contingent consideration.

scPharmaceuticals insider report: A director, Frederick M. Hudson, filed a Form 4 reporting cancellation/conversion of outstanding company stock options in connection with a merger. On 10/07/2025 options with exercise prices below $5.35 were cancelled and converted into cash consideration equal to the excess of $5.35 over each option's exercise price, plus one contingent value right (CVR) per underlying share. The filing lists four cancelled option grants totaling 72,174 underlying shares (30,000; 19,750; 16,300; 6,124) with exercise prices of $3.85, $4.11, $4.53 and $3.37, and expiration dates ranging from 06/18/2029 to 06/03/2035. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.

scPharmaceuticals Inc. reporting person Rachael Nokes (CFO and Treasurer) reported transactions tied to a merger with MannKind Corporation. On 10/07/2025 a tender offer and subsequent merger completed under a Merger Agreement that provided $5.35 per share in cash plus one non-tradable contingent value right (CVR) per share, with CVRs eligible for up to $1.00 aggregate upon certain milestones.

As a result, 30,386 directly held common shares were disposed and 125,675 other common shares (including RSUs) were surrendered for cash and CVRs, leaving 0 shares held following the transactions. Outstanding options with exercise prices below $5.35 were cancelled and cashed out for the excess value, and corresponding RSU awards were converted into cash and CVRs per the agreement.